Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of QX005N in adults with prurigo nodularis
CTR20241660Phase 3Completed
- Sponsor
- Quxin Biopharmaceutical
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QX005N in prurigo nodularis (PN), sponsored by Quxin Biopharmaceutical. Started May 2024; status: completed.
02
Drugs
QX005N
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20241660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241660.